Chestnut Hill, MA, United States of America

Jing Ni



Average Co-Inventor Count = 3.7

ph-index = 1


Location History:

  • Boston, MA (US) (2021)
  • Chestnut Hill, MA (US) (2022)

Company Filing History:


Years Active: 2021-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jing Ni in Cancer Treatment

Introduction

Jing Ni is an accomplished inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of cancer treatment, particularly in addressing brain metastases. With a total of 2 patents, his work focuses on innovative therapeutic methods that combine various agents to enhance treatment efficacy.

Latest Patents

Jing Ni's latest patents include:

1. **Methods for treating brain metastases using combinations of anti-PI3K and anti-mTOR agents** - This invention relates to methods of treating brain metastases using synergistic combinations of anti-PI3K and anti-mTOR therapies. It has been determined that blocking PI3K and mTOR provides therapeutic benefits for treating brain metastases.

2. **Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders** - This invention involves the use of pyrimido-diazepinone compounds that can modulate protein kinases such as PI3K-γ and PI3K-δ. These compounds are utilized in the treatment of various diseases, disorders, or conditions.

Career Highlights

Jing Ni is currently associated with the Dana-Farber Cancer Institute Inc., where he continues to advance research in cancer therapies. His work is pivotal in developing new treatment strategies that can significantly improve patient outcomes.

Collaborations

Some of his notable coworkers include Jean Zhao and Shaozhen Xie, who contribute to the collaborative efforts in research and development at the institute.

Conclusion

Jing Ni's innovative work in cancer treatment exemplifies the impact of research and invention in the medical field. His patents reflect a commitment to improving therapeutic options for patients with brain metastases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…